GHRP-6
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
GHRP-6 is listed as endocrine / ghrp.
- •GH secretagogue
- •Appetite stimulation
- •Body composition
Regulatory status: Not FDA-approved; research use.
Structure & Properties
Compound: GHRP-6; also known as Growth Hormone Releasing Peptide-6.
Pharmacologic class: Endocrine / GHRP.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
GHS-R1a agonist — stimulates GH release; pronounced ghrelin-like appetite stimulation; gastroprotective properties.
- •Appetite support in wasting states
- •GH release
- •Gastroprotective in models
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Pre-clinical and observational; limited Phase I
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
2–3× daily fasted. Strong appetite stimulation — avoid pre-sleep if weight loss is a goal.
Potential interactions and combinations to avoid
- •Ipamorelin, GHRP-2, Hexarelin — same class
- •MK-677
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Strong hunger stimulation
- •Cortisol and prolactin elevation
- •Desensitization
Contraindications
- •Active malignancy
- •Pregnancy
- •Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- •Active or untreated diabetic retinopathy
- •Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- •Untreated hypothyroidism or uncorrected adrenal insufficiency
- •Acromegaly, pituitary adenoma, or intracranial hypertension
- •Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- •Critical illness after acute surgery, trauma, or respiratory failure
- •Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 100–300 mcg/dose
Frequency: 1–3× daily
Cycling: 8–12 weeks on / 4 weeks off.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Mod GRF 1-29 / CJC-1295 for GH synergy
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is GHRP-6?
In plain words
GHRP-6 is a peptide, a compound made of linked amino acids. It signals the body to release growth hormone and strongly increases hunger. Researchers study it for growth hormone release and appetite stimulation. Evidence is limited to early laboratory and observational research, and it is not FDA-approved.
Technical definition
GHRP-6 (Growth Hormone Releasing Peptide-6) is a peptide-class endocrine compound and growth hormone (GH) secretagogue that activates the growth hormone secretagogue receptor GHS-R1a to stimulate GH release. It produces pronounced ghrelin-like appetite stimulation and has gastroprotective properties; reported risks include strong hunger, cortisol and prolactin elevation, and desensitization. It is not FDA-approved and is designated for research use, with evidence limited to preclinical and observational findings.
Function
Dosing
Recommended Time of Day
Fasted — morning and pre-bed; expect hunger ~15 min after dosing.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
8–12 weeks on / 4 weeks off.
Timing & Interactions
- ·Ipamorelin, GHRP-2, Hexarelin — same class
- ·MK-677
- ·Mod GRF 1-29 / CJC-1295 for GH synergy
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on GHRP-6 and sync them to Vial Lab.
Benefits
- ·Appetite support in wasting states
- ·GH release
- ·Gastroprotective in models
Risks
- ·Strong hunger stimulation
- ·Cortisol and prolactin elevation
- ·Desensitization
Contraindications
- ·Active malignancy
- ·Pregnancy
- ·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- ·Active or untreated diabetic retinopathy
- ·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- ·Untreated hypothyroidism or uncorrected adrenal insufficiency
- ·Acromegaly, pituitary adenoma, or intracranial hypertension
- ·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- ·Critical illness after acute surgery, trauma, or respiratory failure
- ·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Not FDA-approved; research use
Veterinary Use (Pets)
No established veterinary protocol for GHRP-6. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.